-
STAT+: Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line
18 Oct 2025 20:29 GMT
… ’s annual conference show the drug can have powerful benefits for … and Daiichi Sankyo, the findings from the two trials could expand the drug … reflect how drugs like Enhertu — what are known as antibody-drug conjugates …
-
Cancer drug startup Tubulis raises $361 million for ADCs
15 Oct 2025 15:39 GMT
… :
Tubulis, an antibody-drug conjugate developer based in Germany … .
Dive Insight:
Antibody-drug conjugates, or ADCs, became … AstraZeneca and Daiichi Sankyo’s Enhertu. The drug has been … Tubulis, a German antibody-drug conjugate developer.
Permission granted …
-
ESMO: AZ, Daiichi unleash Enhertu's 2-fisted power, aiming to reshape early breast cancer landscape
18 Oct 2025 18:44 GMT
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a … Roche’s rival antibody-drug conjugate Kadcyla, Enhertu significantly … . The rate of adjudicated drug-related interstitial lung disease, … it will affect the drug’s overall treatment duration …
-
<![CDATA[T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease]]>
18 Oct 2025 18:59 GMT
… ) and those associated with drug discontinuation (17.9%; drug-related ILD… distributions of any-grade adjudicated drug-related ILD events with sequential … for the current presentation from Daiichi Sankyo and AstraZeneca.
References
Geyer CE …
-
<![CDATA[Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer ]]>
18 Oct 2025 18:59 GMT
… surface events, and adjudicated drug-related interstitial lung disease … a TROP2-directed antibody-drug conjugate (ADC) … 3, 0%), and adjudicated drug-related interstitial lung disease … Pharma, AstraZeneca, Eisai, Jazz, Daiichi Sankyo, Gilead, Indivumed, LG Chem …
-
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
18 Oct 2025 15:43 GMT
… . Last year, the Daiichi Sankyo-partnered drug generated $1.98 billion … topped every other cancer drug in AstraZeneca's … chemotherapy. Like chemotherapy, antibody drug conjugates, or ADCs, use … to win Food and Drug Administration approval.
AstraZeneca Stock …
-
Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer
18 Oct 2025 18:27 GMT
AstraZeneca (NASDAQ:AZN) and partner Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) on … early breast cancer.
The antibody-drug conjugate is currently indicated in …
-
AstraZeneca’s Enhertu shows promise in early-stage breast cancer treatment
18 Oct 2025 15:09 GMT
… (Reuters) -AstraZeneca and Daiichi Sankyo’s drug Enhertu has shown strong … Congress, indicate that the drug, currently used for advanced … of medicines called antibody-drug conjugates (ADC), also … , global oncology head at Daiichi Sankyo – “Any place where …
-
Lung Cancer Antibody Drug Conjugates Market Size FDA Approved Lung Cancer ADC Clinical Trials Future Opportunity Insight
14 Oct 2025 18:19 GMT
… Indication and Phase
Cancer Antibody Drug Conjugates Development Platforms By Company … with the efficacy of chemotherapy drugs, ADCs specifically target cytotoxic agents … players. Pharmaceutical giants such as Daiichi Sankyo, Pfizer, and Roche are developing …
-
Merck reports phase 3 KEYNOTE─B96 trial meets secondary endpoint of OS in all comers population of patients with platinum─resistant recurrent ovarian cancer
18 Oct 2025 07:55 GMT
… -Ovarian01 trial in collaboration with Daiichi Sankyo evaluating raludotatug deruxtecan (R-DXd … by the US Food and Drug Administration (FDA) for the treatment … discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck …
About
© 1995-2025